Molecular genetic markers as predictors of response to chemotherapy in gliomas
Idbaih A, Omuro A, Ducray F, Hoang-Xuan K. Molecular genetic markers as predictors of response to chemotherapy in gliomas. Current Opinion In Oncology 2007, 19: 606-611. PMID: 17906460, DOI: 10.1097/cco.0b013e3282f075f3.Peer-Reviewed Original ResearchConceptsAnaplastic oligodendroglial tumorsLow-grade gliomasProspective trialMGMT statusOligodendroglial tumorsIndependent favorable prognostic factorFavorable prognostic factorRelevant prognostic markerPredictors of responsePromoter methylationTreatment of gliomaPredictor of chemosensitivityMGMT promoter methylationObjective responsePrognostic factorsRetrospective studyPrognostic markerSuch tumorsTreatment decisionsChromosome 1p/19q codeletionMGMT inactivationPredictive valueChemotherapyGliomasLow expressionTemozolomide for low-grade gliomas
Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard M, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon J, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre J, Hoang-Xuan K. Temozolomide for low-grade gliomas. Neurology 2007, 68: 1831-1836. PMID: 17515545, DOI: 10.1212/01.wnl.0000262034.26310.a2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, AlkylatingBrain NeoplasmsChromosome DeletionChromosomes, Human, Pair 1Chromosomes, Human, Pair 19DacarbazineDNA Mutational AnalysisDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticGenetic TestingGenotypeGliomaHumansLoss of HeterozygosityMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesSurvival RateTemozolomideTreatment OutcomeConceptsProgression-free survivalLow-grade gliomasProgressive low-grade gliomaObjective responseMedian progression-free survivalLonger progression-free survivalSingle-center observational studyCenter observational studyMaximum tumor responseStable diseaseProgressive diseaseAdult patientsConsecutive patientsOverall survivalMedian timeTMZ cyclesTemozolomide chemotherapyCentral reviewTumor responseFavorable outcomeMedian numberObservational studyPatientsPredictive impactConventional schedule